Recruiting
Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease
The purpose of this study is to develop and evaluate the usefulness of hyperpolarized (HP) 129Xe gas MRI for regional assessment of pulmonary function.
ClinicalTrials.gov IDNCT04624490
PhasePHASE1
Enrollment260
SponsorMario Castro, MD, MPH
Age3 Years
SexALL
Conditions studied
Asthma, COPD, Interstitial Lung Disease, Cystic Fibrosis, Pulmonary Hypertension, Pulmonary Infection, Other Lung Disease
About this study
The purpose of this study is to develop and evaluate the usefulness of hyperpolarized (HP) 129Xe gas MRI for regional assessment of pulmonary function.
Interventions
- Drug: Hyperpolarized Xe129 — During MRI scanning, subject will inhale hyperpolarized xenon gas for a maximum of 16 seconds per scan, with a maximum of 4 MR scans + Calibration in a given imaging session.
Primary outcomes
- RBC/Barrier Ratio (Day 1)
Eligibility information
Inclusion Criteria:
Healthy Volunteers:
* Subject has no diagnosed pulmonary conditions
* Ability to read and understand English or Spanish
Subjects with Lung Disease:
* Subject has a diagnosis of pulmonary dysfunction made by a physician
* No acute worsening of pulmonary function in the past 30 days
* Ability to read and understand English or Spanish
Exclusion Criteria:
* MRI is contraindicated based on responses to MRI screening questionnaire
* Subject is pregnant or lactating
* Subject does not fit into 129Xe vest coil used for MRI
* Subject cannot hold his/her breath for 15-16 seconds
* Subject deemed unlikely to be able to comply with instructions during imaging
* Oxygen saturation \<88% on room air or with supplemental oxygen
* Cognitive deficits that preclude ability to provide consent
* Institutionalization
Study locations
- University of Kansas Medical Center, Kansas City, Kansas 66160 United States
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.